Aug 13, 2020
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
Jun 12, 2020
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jun 10, 2020
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
May 20, 2020
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
May 18, 2020
Vaccine Partnering Terms and Agreements Report 2014-2020 - Access to 550+ Vaccine Deal Documents Highlighting Deal Structure, Top Deals by Value, and Most Active Dealmakers
May 04, 2020
BiondVax Announces Upcoming Expiration of Public Warrants
Mar 24, 2020
New Directors Elected to BiondVax's Board of Directors
Mar 19, 2020
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
Feb 05, 2020
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
Jan 16, 2020
BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
Nov 26, 2019
BiondVax Announces Third Quarter 2019 Financial Results and Business Update
Nov 18, 2019
Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
Oct 07, 2019
BiondVax Receives EUR4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
Aug 28, 2019
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
Aug 08, 2019
Global Vaccine Contract Manufacturing Market 2019-2030 by Service Portfolio, Expression System Used, Scale of Operation, Size of Manufacturers, Geography
Jul 16, 2019
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
Jul 08, 2019
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
Jun 26, 2019
European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to EUR24million
Jun 18, 2019
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
Jun 10, 2019
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process